2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2009
Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection
Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009, 104: 1881-1890. PMID: 19712125, PMCID: PMC2763027, DOI: 10.1111/j.1360-0443.2009.02687.x.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis C virusRespondent-driven samplingPrevalent infectionMajority of IDUsHepatitis C virus infectionSustained virological responseC virus infectionRespondent-driven sampleAssociation of genotypesIDU communityVirological responseHCV infectionAntiviral therapyC virusGenotype 3aDrug injectionVirus infectionDrug injectorsBlood samplesHCV sequencesDrug usersEndemic infectionInfectionMolecular epidemiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply